Our Scottish research is mainly based at The University of Glasgow, but we are also funding a project at The University of Edinburgh. 

We are supporting basic science that’s unravelling the underlying biology of blood cancer, so we can start to understand what drives the disease, and design drugs to target these processes. And we are delivering benefits to people affected by blood cancer through our TAP clinical trials that are being co-ordinated through The Beatson West of Scotland Cancer Centre in Glasgow. Two TAP trials are being led from Glasgow that is looking at a new treatment combination for people with myeloproliferative neoplasms (MPNs), and trialling a new tyrosine kinase inhibitor (TKI) in advanced chronic myeloid leukaemia (CML).

We have a strong focus on CML research, but we are also supporting projects in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL).

The University of Edinburgh

Chemotherapy is commonly used to treat non-Hodgkin lymphoma (NHL), and can be very effective. But the side-effects of chemotherapy can be highly toxic and many people with NHL can become resistant to their treatment, or relapse. 

Professor Chris Gregory and his team are pioneering research into more targeted treatments for people with NHL by investigating how the cancer cells interact with the immune system. They are focussing on white blood cells called macrophages, which normally help our bodies fight infections. But cancer cells can hijack macrophages to control the environment surrounding them, something called a ‘microenvironment’, which can influence how people respond to treatment. 

Professor Gregory’s research has already revealed many surprising interactions between tumours and macrophages. One of these is that when tumour cells die, they attract macrophages by sending out chemical signals, which in turn helps the tumour to grow. Now Professor Gregory wants to examine this and other biological processes in order to determine exactly how dying tumour cells hijack the body’s immune response to support cancer growth.

Targeting AML that’s not responding to treatment

Lead researcher - Professor Elaine Dzierzak, University of Edinburgh
Acute myeloid leukaemia (AML)
Does GPR56 confer self-renewal properties on human hematopoietic stem cells and leukemic stem cells?
Acute myeloid leukaemia can be very difficult to treat, with some forms of the disease refusing to respond to current treatments. Professor Dzierzak and her team are exploring what role a protein called GPR56 might play in treatment-resistant AML, and whether preventing it from working could offer a new treatment option.

How does leukaemia develop in babies?

Lead researcher - Professor Katrin Ottersbach, University of Edinburgh
Childhood acute lymphoblastic leukaemia (Ch-ALL)
Mechanism of lineage switching and the role of the cell-of-origin in MLL-rearranged infant leukaemia
Professor Ottersbach is investigating the genetic errors that occur before birth and cause some babies to develop leukaemia. By improving how well this process is understood, her research will open the door to better and kinder treatments for babies with leukaemia.

University of Glasgow

Our research at The University of Glasgow is searching for cures for people with CML, and we are finding new ways to target CLL. Our TAP centre is based in Glasgow, and we have trials that are looking at new treatments for people who are in the advanced stages of MPN or CML. 

With the advent of targeted tyrosine kinase inhibitors (TKIs) for CML, most people living with this blood cancer can now take a single pill and control their disease. But they are not completely cured, and some people are unable to tolerate the side effects of their treatment, or become resistant to it, or find that their CML has come back. 

Over the last few years, Professor Holyoake along with Dr David Vetrie have been focusing on leukaemia stem cells that maintain the leukaemia in the bone marrow. Although these slow growing cells make up only a tiny proportion of the total population of cancer cells, they can produce a steady stream of new CML cells. And because they are less active than the other cancer cells, they are harder to target with current drugs, and that is why the disease is difficult to eradicate completely.

Researchers have now identified three key cellular networks that are crucial in controlling survival of CML stem cells. Now the team want to see how these networks interact with each other, and how they may be targeted with new drugs to improve the outcome for people with CML. 

We are also supporting research that is hoping to find new treatments and combinations of drugs for chronic lymphocytic leukaemia (CLL). Although the majority of people initially respond to conventional chemotherapy, many will relapse due to the re-emergence of CLL cells that evaded initial treatment. In these cases, people with CLL can quickly run out of options. 

It is now appreciated that the CLL cells interact with several types of other surrounding cells within the lymph nodes and bone marrow. These healthy cells are manipulated by the CLL cells so they offer protection from currently-used treatments, such as chemotherapy. 

Dr Alison Michie and her team are focussing on a protein called mTor, which plays a central role in regulating key proteins responsible for CLL cell protection, survival and disease progression. By understanding the role mTOR plays in CLL, researchers hope to find new drug targets that could stop or reverse the disease. 

We are supporting two Trials Acceleration Programme (TAP) studies which are based at The Beatson West of Scotland Cancer Centre in Glasgow. 

Myeloproliferative Neoplasms (MPNs) are rare blood cancers that in some cases may transform to an acute leukaemia which is very difficult to treat. When MPN progresses to the advanced ‘blast phase’, treatment options are very limited. And while progress continues to be made in managing early phase MPN, research into the advanced stage of the disease has been relatively neglected so far.

Dr Mark Drummond is running the PHAZAR trial, which wants to see if combining a biological therapy called ruxolitinib with azacitidine, a chemotherapy, could offer a new approach to treat people with advanced MPN. On their own, ruxolitinib has been shown to be effective at controlling MPN symptoms, and azacitidine has improved survival in people with a type of MPN called myelodysplastic syndrome (MDS), and AML. The aim of the trial is to find a safe dose of azactidine and ruxolitinib when combined, see how well treatment works, and to find out more about the side effects in people with advanced MPN.

Professor Mhairi Copland is leading another TAP trial called MATCHPOINT, which is looking at treatment options for people who are in an advanced blast phase of their CML. 

Although TKIs work for many people with CML, this improvement remains limited to people who receive TKI treatment whilst in the chronic phase of their disease. Unfortunately, the majority of people whose disease has progressed to blast phase have already received all the available drugs in succession during the chronic phase, so there is no TKI available when they progress. If this happens, people are usually given intensive treatment comprising high dose of chemotherapy alongside a TKI, and then a stem cell transplant.

MATCHPOINT is looking at a conventional chemotherapy regimen called FLAG-IDA alongside a new TKI drug called ponatinib for people who are in the blast phase of their CML and who have had a stem cell transplant. Ponatinib works in a similar way to imatinib and nilotinib, in that it specifically targets BCR-ABL that is only found in CML cells. However, ponatinib was also designed to target mutated forms of the BCR-ABL that arise in people who become resistant to their TKI treatment, as well as other kinases implicated in blood cancer and solid tumours.

If found to be safe, researchers hope that this combination of drugs can be used in future trials to see whether we can improve the outlook for people with CML who are in blast phase.

Overcoming drug resistance and improving cure rates

Lead researcher - The late Professor Tessa Holyoake and Dr David Vetrie, University of Glasgow
Leukaemia Chronic myeloid leukaemia (CML)
Targeting p53, c-Myc and PRC2 regulatory hubs: A systematic and stratified approach to deliver new therapeutics for CML
Following work by the late Professor Tessa Holyoake, Dr David Vetrie and his team are finding ways to predict which people with CML will do well on TKIs, and those that will require alternative approaches. The team are investigating how networks of proteins in leukaemia stem cells work together to aid cancer cell survival, and how they may be targeted with new drugs. This research hopes to significantly improve CML cure rate, and provide new forms of treatment for people with drug resistance and advanced phase disease.

Searching for a cure for CML

Lead researcher - Dr David Vetrie, University of Glasgow
Leukaemia Chronic myeloid leukaemia (CML)
Crosstalk between PRC2 and BCL6 in regulating CML stem cell survival: From epigenomics to novel therapeutic approaches
Dr Vetrie is studying how two proteins called EZH2 and BCL6 work together in leukaemic stem cells. This project will help to understand the biology behind the function of these two proteins, and allow researchers to design better ways to treat and eventually cure CML.

New drug targets for CLL

Lead researcher - Dr Alison Michie, University of Glasgow
Leukaemia Chronic lymphocytic leukaemia (CLL)
Elucidating the role of individual mTor complexes during the development and progression of chronic lymphocytic leukaemia
Dr Michie and her team are looking at a particular protein called mTor, which plays a central role in regulating key proteins responsible for CLL cell protection, survival and disease progression. As mTor represents a promising drug target, Dr Michie wants to gain more information about the biological function of this protein.

Reapplying the brakes in out of control CLL cells

Lead researcher - Dr Alison Michie, University of Glasgow
Chronic lymphocytic leukaemia (CLL)
Elucidating the mechanisms that regulate FOXO activity in chronic lymphocytic leukaemia – a novel target for therapeutic exploitation?
A group of proteins called FOXO can work like brakes in our cells, preventing them from growing too quickly. However, in chronic lymphocytic leukaemia (CLL), FOXO proteins can’t do their jobs properly. Dr Michie is exploring ways to reverse this, which may highlight a new way to treat CLL.

Shutting down the power in leukaemia stem cells

Lead researcher - Dr Vignir Helgason, University of Glasgow
Acute myeloid leukaemia (AML) Chronic myeloid leukaemia (CML)
Targeting mitochondrial fuel oxidation for the treatment of chronic and acute myeloid leukaemias
Current treatments are unable to completely kill the leukaemia stem cells, which can cause the disease to return. Dr Helgason and his team are exploring how stem cells in chronic myeloid leukaemia and acute myeloid leukaemia break down nutrients to make energy. By understanding more about this process, they hope to develop new treatments that target stem cells.